See more : Kehua Data Co., Ltd. (002335.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Absci Corporation (ABSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Absci Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kintara Therapeutics, Inc. (KTRA) Income Statement Analysis – Financial Results
- Dr. Soliman Abdel Kader Fakeeh Hospital Company (4017.SR) Income Statement Analysis – Financial Results
- Evergreen Aviation Technologies Corporation (2645.TW) Income Statement Analysis – Financial Results
- Austin Engineering Limited (ANG.AX) Income Statement Analysis – Financial Results
- Atishay Limited (ATISHAY.BO) Income Statement Analysis – Financial Results
Absci Corporation (ABSI)
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Cost of Revenue | 47.57M | 13.04M | 6.65M | 11.45M | 4.31M |
| Gross Profit | -41.85M | -7.29M | -1.87M | -6.67M | -2.25M |
| Gross Profit Ratio | -731.88% | -126.85% | -39.15% | -139.50% | -109.27% |
| Research & Development | 48.07M | 58.91M | 44.59M | 11.45M | 4.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.83M | 40.55M | 28.78M | 5.50M | 3.52M |
| Other Expenses | 35.33M | 13.04M | 6.65M | 1.13M | 491.00K |
| Operating Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Cost & Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Interest Income | 0.00 | 972.00K | 3.43M | 634.00K | 268.00K |
| Interest Expense | 1.01M | 972.00K | 3.43M | 634.00K | 268.00K |
| Depreciation & Amortization | 14.00M | 13.04M | 6.65M | 1.13M | 491.00K |
| EBITDA | -95.46M | -91.36M | -99.77M | -12.59M | -5.83M |
| EBITDA Ratio | -1,669.41% | -1,589.63% | -2,086.43% | -263.35% | -282.77% |
| Operating Income | -115.52M | -106.75M | -75.24M | -13.30M | -6.27M |
| Operating Income Ratio | -2,020.20% | -1,857.49% | -1,573.36% | -278.26% | -304.13% |
| Total Other Income/Expenses | 5.05M | 1.39M | -34.62M | -1.05M | -319.00K |
| Income Before Tax | -110.47M | -105.37M | -109.86M | -14.35M | -6.58M |
| Income Before Tax Ratio | -1,931.90% | -1,833.39% | -2,297.34% | -300.27% | -319.61% |
| Income Tax Expense | 100.00K | -461.00K | -8.90M | 216.00K | 217.00K |
| Net Income | -110.57M | -104.90M | -100.96M | -14.57M | -6.80M |
| Net Income Ratio | -1,933.65% | -1,825.37% | -2,111.25% | -304.79% | -330.15% |
| EPS | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| EPS Diluted | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| Weighted Avg Shares Out | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
| Weighted Avg Shares Out (Dil) | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.
Absci Corp up 50% after announcing research collaboration with Merck
Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company came to this agreement via its AI-powered Integrated...
DOGZ Alert: Why Pet Penny Stock Dogness Is Running Higher Today
Dogness (DOGZ) stock is on a run Friday as investors react to recent volatility surrounding the shares alongside heavy trading. The post DOGZ Alert: Why Pet Penny Stock Dogness Is Running Higher Today appeared first on InvestorPlace.
ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today
Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK). The post ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today appeared first...
Why Absci Shares Are Soaring Today
Absci Corp (NASDAQ: ABSI) is trading higher Friday after the company announced a research collaboration with Merck & Co Inc (NYSE: MRK). The collaboration will utilize Absci's AI-powered Integrated Drug Creation Platform.
Absci stock rockets after collaboration with Merck could lead to more than $600 million in payments
Shares of Absci Corp. ABSI, -12.78% skyrocketed 59.1% on heavy volume in premarket trading Friday, after the biotechnology company said it could be eligible to receive up to $610 million in upfront fees and milestone payments from Merck & Co....
Absci Stock (ABSI): Why The Price Surged Today
The stock price of Absci Corp (NASDAQ: ABSI) increased by over 30% pre-market today. This is why it happened.
Absci to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
VANCOUVER, Washington, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in...
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index
ATLANTA & NEW YORK--(BUSINESS WIRE)--Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday,...
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
CAMBRIDGE, Mass. & BEIJING & DUBAI, United Arab Emirates--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and NewBridge Pharmaceuticals, a specialty...
Source: https://incomestatements.info
Category: Stock Reports